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Introduction: Muscle sympathetic nerve activity (MSNA) may play a role in insulin
resistance in obesity. However, the direction and nature of the relationship between
MSNA and insulin resistance in obesity remain unclear. We hypothesized that resting
MSNA would correlate inversely with both muscle and liver insulin sensitivity and that it
would be higher in insulin-resistant vs. insulin-sensitive subjects.
Materials and methods: Forty-five non-diabetic obese subjects were studied. As
no significant relationships were found in women, the data presented in on 22 men
aged 48 ± 12 years. Two-step (15 and 80 mU/m2/min) hyperinsulinaemic-euglycaemic
clamps were performed using deuterated glucose to determine liver and muscle insulin
sensitivity. Clinical and metabolic parameters were assessed. MSNA was measured via
a microelectrode inserted percutaneously into the common peroneal nerve.
Results: MSNA burst frequency correlated inversely with liver insulin sensitivity
(r = −0.53, P = 0.02) and positively with the hepatokines C-reactive protein (CRP)
and fibroblast growth factor (FGF)-19 (r = 0.57, P = 0.006, and r = −0.47, P = 0.03,
respectively). MSNA burst frequency was lower in Liversen compared to Liverres (27 ± 5
vs. 38± 2 bursts per minute; P= 0.03). Muscle insulin sensitivity was unrelated toMSNA.
Discussion: Sympathetic neural activation is related to liver insulin sensitivity and
circulating hepatokines CRP and FGF-19 in non-diabetic obese men. These results
suggest a potential hepato-endocrine-autonomic axis. Future studies are needed to
clarify the influence of MSNA on liver insulin sensitivity in men.
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INTRODUCTION
The sympathetic nervous system (SNS) plays an important role
in homeostasis and metabolism, influencing resting metabolic
rate, energy expenditure, and glucose and lipid metabolism
(Astrup et al., 1995; Stob et al., 2007). Restingmuscle sympathetic
nerve activity (MSNA) regulates vasoconstriction, and is a major
determinant in the control of blood pressure. MSNA has been
shown to be higher in normotensive obese vs. lean individuals
(Scherrer et al., 1994; Grassi et al., 1995). It has also been shown
to decrease with weight loss (Straznicky et al., 2010).
Obesity is associated with insulin resistance and other
metabolic complications, possibly contributed to by impaired
sympathetic nerve activity. Hyperinsulinaemia is commonly
observed in obesity; it is closely linked to peripheral and
hepatic insulin resistance and has been shown to stimulate
MSNA in humans (Landsberg, 1996; Greenfield and Campbell,
2008). Higher baseline MSNA and a blunted MSNA response
to oral glucose is a characteristic of obese insulin-resistant
individuals when defined by indirect oral glucose tolerance
test (OGTT) indices (Straznicky et al., 2009). However,
the nature and direction of the association between SNS
activity and peripheral and hepatic insulin resistance remain
unclear.
Muscle sympathetic nerve activity, measured directly using a
microelectrode inserted percutaneously into a peripheral nerve
(microneurography), is a reliable and reproducible assessment
of sympathetic nerve activity (Grassi and Esler, 1999). Although
MSNA accounts for only about 20% of whole body release
of norepinephrine to plasma, it has been shown to be closely
related to cerebral, cardiac, and renal noradrenaline spillover
(Wallin et al., 1992, 1996; Lambert et al., 1997; Straznicky
et al., 2008). There is a gender difference in MSNA among
obese individuals (Brooks et al., 2015). MSNA has been
shown to correlate with Body Mass Index (BMI), visceral
adiposity, and waist circumference in obese men (Lambert
et al., 2007), but not in premenopausal or postmenopausal
women (Brooks et al., 2015). The reasons for this gender
specificity are not completely understood, but it is proposed to
relate to differences in adipose tissue disposition, inflammatory
profiles, and pressor and depressor components of the renin
aldosterone angiotensin system (Fischer et al., 2002; Brooks
et al., 2015). Estrogen may play a role in resisting obesity-
induced hypertension and MSNA elevation by suppressing
inflammatory cytokines and reducing production and actions
of pressor renin-aldosterone system components (Brooks et al.,
2015), supported by differences observed in MSNA correlations
between pre and postmenopausal women (Brooks et al.,
2015).
We evaluated resting MSNA in 45 non-diabetic obese subjects
who had undergone a two-step hyperinsulinaemic-euglycaemic
clamp with deuterated glucose to assess liver and muscle insulin
sensitivity (Chen et al., 2015). We hypothesized that resting
MSNA would be correlated with both muscle and liver insulin
sensitivity and that in subjects matched for adiposity, MSNA
would be higher in liver and muscle insulin-resistant subjects
compared to their insulin-sensitive counterparts.
MATERIALS AND METHODS
This is a subcomponent of a parent study that has been reported
elsewhere (Chen et al., 2015). One hundred and eighty-four
subjects aged 21–69 years were recruited from the general
population by advertisements in local newspapers. The study
was approved by St Vincent’s Hospital Human Research Ethics
Committee, Sydney. Subjects provided informed written consent
prior to commencement of the study, which was conducted
under the guidelines of the Declaration of Helsinki. Exclusion
criteria were known renal, cardiac or liver disease, or active
cancer and diabetes,>5% change in body weight in the preceding
3 months, medications that affect glucose metabolism (including
diabetes medications, anti-psychotics and steroids) and >20 g
of alcohol; based on these criteria 104 potential participants
screened over the phone were excluded from the study.
The remaining 80 subjects underwent standard OGTT.
Diabetes was defined according to the American Diabetes
Association criteria (American Diabetes Association, 2014).
Fourteen subjects were excluded due to difficult venous access
or loss of interest. Of the 66 subjects remaining, all agreed to
undergo MSNA studies; 45 (22 males) were successfully studied.
Twenty one subjects (7 males) did not have successful MSNA
recording due to technical issues or poor recording quality.
As no relationships were found between MSNA indices and
insulin resistance in females, data on males only are presented.
No subject was treated with beta-blockers. Clamp studies were
performed at the Clinical Research Facility at the Garvan Institute
of Medical Research, Sydney as previously described (Milner
et al., 2010). Recording of MSNA was performed at Neuroscience
Research Australia (NeuRA), Sydney and magnetic resonance
imaging (MRI) and dual-energy X-ray absorptiometry (DXA) at
St Vincent’s Hospital, Sydney.
Definition of Insulin Sensitivity in Muscle
and Liver
All subjects underwent two-step (insulin infusion rates 15 and
80 mU/m2/min) hyperinsulinaemic-euglycaemic clamps with
deuterated glucose (6,6-2H2, Cambridge isotope, Andover) to
assess muscle and liver insulin sensitivity as described previously
(Milner et al., 2010; Petersons et al., 2013; Chen et al., 2015). The
percentage of endogenous glucose production (EGP) suppression
with low-dose insulin was used to define liver insulin sensitivity.
Liver insulin-sensitive men (Liversen) were defined as the
top tertile of EGP suppression and liver insulin-resistant men
(Liverres) as the bottom two tertiles, as previously described
(Chen et al., 2015). The cut-off was based on an average
prevalence of 30% insulin-sensitive obesity amongst the obese
population in large cohort studies (Pataky et al., 2010).
Muscle insulin sensitivity was inferred from the glucose
infusion rate (GIR) during the high-dose insulin clamp (GIRHI)
adjusted for fat-free mass (FFM). Study participants were
assigned to the muscle insulin-sensitive (Musclesen) group if
GIRHI was in the top tertile of the cohort and to the muscle
insulin-resistant (Muscleres) group if in the bottom two tertiles.
Our Musclesen group had comparable GIRHI to that measured
in a group of lean healthy individuals previously studied in
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our Clinical Research Facility using a similar protocol (Tonks
et al., 2013). As EGP was fully suppressed during the high-
dose insulin infusion, GIRHI reflects peripheral (mainly muscle)
insulin sensitivity.
Anthropometry and Body Composition
BMI was defined as weight in kilograms divided by height in
meters squared. Waist circumference was measured as the widest
circumference between the lower end of the ribs and the anterior
superior iliac spines. Hip circumference was measured at the
widest circumference between the greater trochanters and the
anterior superior iliac spines. Total body fat mass, FFM and
central abdominal fat were measured by DXA (Lunar Prodigy,
GE-Lunar, Madison, WI, USA; S/ware 12.20). In some larger
subjects, analysis was performed by aligning one side of the body
on the scanner, and doubling the data to achieve overall body
composition, as previously described (Chen et al., 2015).
Magnetic Resonance Imaging
MRI (3.0 T Philips Achieva, Philips Medical Systems, The
Netherlands) images were acquired using the mDIXON
technique to evaluate the amount of liver and subcutaneous fat.
The amount of visceral adipose tissue was measured in five slices
at the L4/L5 intervertebral disc level and quantified using Image
J software 1.46r (NIH, USA). As described previously (Milner
et al., 2010; Chen et al., 2015), visceral fat was calculated as the
difference between total fat and subcutaneous fat. One subject
was over the weight limit of the MRI machine and so quantitative
fat data were not available for this subject.
Muscle Sympathetic Nerve Activity and
Blood Pressure Measurement
Measurements of resting MSNA were performed in a quiet
room at 22◦C in the seated position on a separate day to the
clamp study. Subjects voided before commencement. MSNA was
performed in a resting state with one-third of subjects studied
in the afternoon due to attendance at the Garvan Institute in
the morning. Subjects refrained from caffeine for 4 h prior to
recording.
Subjects lay in a chair with their backs at 45◦ angle
and legs supported horizontally. Spontaneous resting
MSNA was recorded by inserting an insulated tungsten
microelectrode (Frederick Haer and Co., Bowdoinham, ME,
USA) percutaneously at the level of the fibular head into the
left common peroneal nerve and advanced toward a muscle
fascicle of the nerve while delivering weak electrical impulses
(0.01–1 mA, 0.2 ms, 1Hz). An uninsulated reference electrode
was inserted subdermally 2–3 cm from the recording electrode
and a surface Ag–AgCl electrode applied to the leg served as
the ground electrode. A muscle fascicle was defined as such if
intraneural stimulation evoked muscle twitches of the ankle,
toe dorsiflexors, or foot everter muscles with no radiating
paraesthesia. Once a muscle fascicle had been entered, neural
activity was amplified (band-pass 0.3–5 kHz, gain 2 × 104)
using an isolated amplifier and headstage (NeuroAmpEx, AD
Instruments, Sydney, Australia). The position of the electrode
was then adjusted manually until spontaneous bursts of MSNA
were identified. Once an acceptable nerve-recording site
was obtained with both visual and acoustic identification of
spontaneous sympathetic bursts, resting measurements were
recorded and stored on computer (10 kHz sampling) using a
computer based data acquisition and analysis system (PowerLab
16SP hardware and LabChart 7 software; AD Instruments).
Continuous non-invasive blood pressure was recorded using
radial artery tonometry (CBM-7000, Colin Corp., Japan). The
ECG (0.3 Hz–1 kHz) was recorded with surface electrodes on the
chest and sampled at 2 kHz and respiration (DC-100 Hz).
MSNA burst amplitudes were measured from the RMS-
processed signal (200ms moving average) using the Peak
Parameters feature of LabChart7 (AD Instruments, Sydney,
Australia). The entire process has been described previously
(Macefield, 2013). MSNA was manually analyzed and expressed
as burst frequency (bursts per minute) and burst incidence
(bursts per 100 heart beats), averaged over 15min. There were
no significant differences in MSNA -measured variables between
subjects in whom MSNA was recorded in the morning or the
afternoon (morning n= 15; afternoon n= 7; independent t-test;
P > 0.47).
Laboratory Analyses
Whole blood glucose was measured using the YSI 2300 STAT
analyzer (Yellow Springs Ohio). Serum insulin and C-peptide
concentrations were measured by radioimmunoassay (Millipore,
St Charles, USA). Plasma lipid profiles were determined by an
automated analyzer (Roche, IN, USA). Serum non-esterified fatty
acids (NEFA) were analyzed by an enzymatic colorimetric assay
(Wako, Osaka, Japan). Serum high sensitivity C-reactive protein
(hsCRP), fibroblast growth factors FGF-19 and FGF-21, total
adiponectin, fatty acid-binding protein 4 (FABP4), lipocalin 2
and retinol-binding protein 4 (RBP4) were analyzed by ELISA
(Antibody and Immunoassay Services at the University of Hong
Kong; Chen et al., 2015). The intra- and inter-assay CVs have
been reported previously (Chen et al., 2015).
Statistical Analysis
Data were expressed as means ± SEM unless otherwise
specified. Non-normally distributed data (serum triglycerides,
insulin, NEFA, hsCRP, FGF-19, and FGF-21) were transformed
logarithmically prior to statistical analysis. Student’s t-test was
used to evaluate significant differences between the different
phenotypes. Correlations were performed using Pearson’s
correlation analysis. Chi-square and Fisher’s exact test were
used to detect differences in timing of MSNA measurement in
Liversen and Liverres groups. P< 0.05 was considered statistically
significant. Statistical analysis was carried out using SPSS version
21 (Chicago, IL, USA).
RESULTS
Baseline characteristics are presented in Table 1. Mean age was
48 ± 2 years and BMI was 34.7 ± 0.7 kg/m2 (range 30.9–46.7
kg/m2). Mean systolic and diastolic blood pressure were 127
± 14 and 83 ± 11 mmHg, respectively. Mean MSNA-derived
measures were 56 ± 17 bursts per minutes and 34 ± 11 burst
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TABLE 1 | Clinical characteristics.
Characteristics
(n = 22)
Age Age (years) 48 ± 12
Adiposity BMI (kg/m2) 34.7 ± 3.3
Waist circumference (cm) 114 ± 9
Whole body fat (kg) 40 ± 7
Fat-free mass (kg) 64 ± 6
Central abdominal fat (kg) 3.7 ± 0.6
Subcutaneous fat (cm2) 441 ± 117
Liver fat (%) 16 ± 15
Blood pressure SBP (mmHg)** 127 ± 14
DBP (mmHg)** 83 ± 11
MSNA-derived measures Burst incidence
(bursts/100 beats)
56 ± 17
Burst frequency
(bursts/min)
34 ± 11
Heart rate (BPM) 66 ± 7
Fasting lipid profile Total cholesterol (mmol/L)∧ 5.0 ± 0.9
LDL cholesterol (mmol/L)∧ 3.3 ± 0.8
HDL cholesterol (mmol/L)∧ 1.1 ± 0.2
Triglycerides (mmol/L)∧8 1.1 (0.8–1.5)
NEFA (mmol/L)8 0.27 (0.25–0.32)
Fasting glycaemic parameters HbA1c (%) 5.5 ± 0.3
Fasting glucose (mmol/L) 4.8 ± 0.4
Fasting insulin (mU/L)8 18 (12–26)
Serum fasting cytokines hsCRP (mg/L)8 2.2 (1.4–4.9)
FGF 19 (ng/L)8 97 (56–152)
FGF 21(ng/L)8 49 (16–159)
FABP 4 (µg/L) 42 ± 17
Lipocalin 2 (µg/L) 44 ± 14
RBP 4 (mg/L) 12 ± 2
Total adiponectin (mg/L) 10 ± 4
Data are means ±SD.
ΦData are median (interquartile range) for non-normally distributed data
**Subjects treated with anti-hypertensive medications excluded from the analysis
(included: n = 18).
∧Subjects treated with lipid lowering medications excluded from the analysis (included:
n = 17).
SBP, systolic blood pressure; DBP, diastolic blood pressure; BPM, beat per minute; LDL,
low density lipoprotein; HDL, high density lipoprotein; hsCRP, highly sensitive C-reactive
protein; FGF, Fibroblast growth factor; FABP4, Fatty acid binding protein 4; RBP4, Retinol
binding protein 4.
per 100 heart beats. Five male subjects reported taking anti-
hypertensive medications. There were no significant differences
in MSNA burst frequency (P = 0.53) and MSNA burst incidence
(P = 0.30) between men taking and not taking anti-hypertensive
medications. Furthermore, no significant differences in average
HbA1c between men treated and men not treated with anti-
hypertensive medications was found (P = 0.86).
Linear Regression Analyses
Liver insulin sensitivity (expressed as EGP suppression)
correlated inversely with MSNA burst frequency (r = −0.53, P
= 0.02; Figure 1), but the inverse relationship with MSNA burst
incidence failed to reach statistical significance (r = −0.36, P
= 0.12). Fasting insulin tended to correlate with MSNA burst
FIGURE 1 | Correlation between liver insulin sensitivity and MSNA
burst frequency in men.
frequency (r = 0.42, P = 0.05), while muscle insulin sensitivity
was not related to either MSNA burst frequency (P = 0.09) or
burst incidence (P = 0.4).
MSNA burst frequency and incidence correlated positively
with hsCRP (Figure 2A and r = 0.45, P = 0.04, respectively).
FGF-19 correlated (Figure 2B) and RBP4 tended to correlate
inversely with MSNA frequency (P = 0.05, Figure 2C).
Factors unrelated to MSNA-derived variables were FGF-21
(Figure 2D), FABP4 (Figure 2E), lipocalin 2 (Figure 2F), and
total adiponectin (P > 0.16).
Age correlated positively with MSNA burst incidence (r =
0.61, P = 0.002), but the relationship to burst frequency failed to
reach statistical significance (r = 0.37, P = 0.09). Systolic blood
pressure, diastolic blood pressure, subcutaneous and liver fat,
serum triglycerides and HbA1c were not related to either MSNA
burst incidence or frequency (P > 0.09).
Stratification by Liver Insulin Sensitivity
Given the significant inverse correlation between MSNA and
liver insulin sensitivity, we stratified the cohort according to
liver insulin sensitivity. The cohort was stratified based on EGP
suppression level to Liversen and Liverres (top tertile vs. bottom
two tertiles, 72% EGP suppression as cut-off value).
Liversen men had lower HbA1c (5.2 ± 0.1 vs. 5.6 ± 0.1%, P =
0.01), fasting insulin (14 [11–22] vs. 25 [17–41] mU/L, P = 0.03)
and hsCRP (1.7 [1.0–2.1] vs. 4.3 [2.2–5.7] mg/L, P = 0.03) than
Liverres men, but had similar age (P = 0.14), BMI (P = 0.79),
central abdominal fat (P = 0.58), and systolic (P = 0.10) and
diastolic (P = 0.66) blood pressure. MSNA burst frequency was
significantly lower in Liversen men compared with Liverres men
(27 ± 5 vs. 38 ± 2; P = 0.03, Figure 3). MSNA burst incidence
tended to be lower in Liversen men (Figure 3, P = 0.06).
DISCUSSION
To our knowledge, this is the first study to directly assess liver
insulin sensitivity and MSNA in obese non-diabetic subjects.
Basal SNS activity measured by MSNA was closely associated
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FIGURE 2 | Pearson’s Correlations between MSNA burst frequency and circulating hepatokines in men. The correlations between MSNA burst frequency
and hsCRP (A), FGF-19 (B), RBP4 (C), FGF-21 (D), FABP4 (E), and lipocalin-2 (F) are reported. ∧P < 0.05 after adjusting for total body fat.
with liver insulin sensitivity in men with obesity. The metabolic
profile of the insulin-sensitive men with obesity in the present
study was consistent with previous reports, including lower
glycaemia, fasting insulin, and CRP (Samocha-Bonet et al., 2012).
The present study highlights the importance of the cytokines CRP
and FGF-19 in their correlations withMSNA in obesemen. These
findings suggest involvement of a potential hepato-endocrine-
sympathetic axis.
We have shown thatMSNAwas lower in liver insulin-sensitive
obese men. Previous studies that used hyperinsulinaemic-
euglycaemic clamps and microneurography (Straznicky et al.,
2012; Curry et al., 2014) did not report any gender specific
differences in the relationship between MSNA and whole body
insulin sensitivity. Nevertheless, these studies included younger
(18–35 years) non-obese (BMI <28 kg/m2) individuals (Curry
et al., 2014) or pre-diabetic and diabetic individuals (Straznicky
et al., 2012), making comparisons with our study difficult. MSNA
has been shown to be regulated differently in men and women
(Scherrer et al., 1994; Lambert et al., 2007).
Previous studies have reported that resting MSNA was higher
in obese insulin-resistant subjects compared to their insulin-
sensitive counterparts when defined by OGTT (Straznicky
et al., 2009). The OGTT-derived Matsuda and Defronzo index
of insulin sensitivity measures a composite of hepatic and
muscle insulin action (Matsuda and DeFronzo, 1999) and our
findings refine these and suggest that the relationship between
insulin sensitivity and resting MSNA reported previously is
predominantly contributed by the liver.
Serum FGF-19 correlated inversely with resting MSNA and
was higher in insulin-sensitive compared with insulin-resistant
men. FGF-19 has been shown to coordinate bile acid and glucose
metabolism (Kharitonenkov et al., 2005). Liver is the main target
organ of FGF-19 action, where FGF-19 binds to the FGFR 4/β-
klotho complex to reduce gluconeogenesis and triglycerides in
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FIGURE 3 | Heart rate, burst incidence and burst frequency measured
by MSNA in obese men stratified by liver insulin sensitivity. Differences
between groups were analyzed by Student T-test, *P < 0.05.
the liver (Cicione et al., 2012). FGF-19 functions in a coordinated
temporal fashion with insulin to inhibit gluconeogenesis and
promote glycogen synthesis after a meal (Cicione et al., 2012).
FGF-19 and insulin may exert differential actions when they
are involved with the SNS, as FGF-19 correlated inversely
with MSNA, compared with a positive correlation between
fasting insulin and MSNA. We also demonstrated a positive
correlation between hsCRP and resting MSNA. While these
associations cannot determine cause and effect, they may suggest
the existence of a hepato-endocrine-autonomic axis, where liver-
related cytokines play a role in regulating sympathetic nerve
activity or vice versa. Further, clamp studies using deuterated
glucose tracers to measure hepatic insulin sensitivity and
noradrenaline spillover to measure sympathetic nerve activity on
larger cohorts are needed to clarify the nature of the associations
between hepatic insulin sensitivity, cytokines and sympathetic
nerve activity.
LIMITATIONS
Our study has some limitations. First, MSNA was not uniformly
measured at the same time of the day. Nevertheless, MSNA
measurements (MSNA burst frequency/incidence) performed
at different times (morning versus afternoon) were not
different. There were also no significant differences between the
proportions of men in the higher MSNA measurement group
(stratified by top tertile of MSNA burst incidence/frequency)
performed in the morning or afternoon (chi-square p > 0.64).
This finding has been supported by previous studies where
MSNA, measured in the non-fasting state, did not differ between
themorning and afternoon (Middlekauff and Sontz, 1995; Hissen
et al., 2015). Second, MSNAmeasured in the peroneal nerve does
not directly assess hepatic sympathetic nerve activity. Third, we
recognize that this is an observational study that cannot infer
causality. Finally, dissociation between regional and systemic
sympathetic nerve activity has been described previously and
regional noradrenaline spillover measurement may have more
precisely assessed regional sympathetic nerve activity (Grassi
and Esler, 1999).
In summary, basal sympathetic outflow to the muscle vascular
bed is lower in insulin-sensitive compared to insulin-resistant
men. RestingMSNA is inversely related to liver insulin sensitivity
and may be mediated by liver-related factors in non-diabetic
obese men. Further studies are needed to examine this putative
hepato-endocrine-autonomic axis.
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